Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06695585 · ClinicalTrials.gov registry record · Phase 4
Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections
A Phase 4 study, sponsored by University of Louisville.
- Not yet
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT06695585 is a Phase 4 study that has not yet begun recruiting, run by University of Louisville. The registered enrollment target is 36 participants.
The verdict
NCT06695585, a Phase 4 study, has not yet begun recruiting, sponsored by University of Louisville.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of our study is to evaluate the efficacy and safety of different volumes of bladder-numbing medication for pain relief at the time of office bladder Botox injections. This is a randomized prospective, double-blind superiority trial comparing 200 ml 2% lidocaine versus 30 ml 2% lidocaine for office Botox injections.
Interventions
- DRUG Lidocaine 2% without vessel constrictor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-12-01 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06695585
The ClinicalTrials.gov registry entry for NCT06695585 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Louisville, which has 217 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lidocaine 2% without vessel constrictor is the first listed.
NCT06695585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06695585 about?
NCT06695585 is a clinical study titled "Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections". The purpose of our study is to evaluate the efficacy and safety of different volumes of bladder-numbing medication for pain relief at the time of office bladder Botox injections. This is a randomized prospective, double-blind superiority trial comparing 200 ml 2% lidocaine versus 30 ml 2% lidocaine ...
What is the current status of trial NCT06695585?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2024-12-01. Estimated completion is 2025-12-01.
What interventions are being tested in trial NCT06695585?
The interventions under investigation include: Lidocaine 2% without vessel constrictor (DRUG).
Who is sponsoring clinical trial NCT06695585?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.